BridgeBio Oncology Therapeutics, Inc.
BBOT
$9.05
$0.171.91%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | ||
|---|---|---|---|---|---|
| Net Income | -80.47% | -- | -- | -- | |
| Total Depreciation and Amortization | 193.27% | -- | -- | -- | |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | |
| Total Other Non-Cash Items | 280.35% | -- | -- | -- | |
| Change in Net Operating Assets | -58.75% | -- | -- | -- | |
| Cash from Operations | -106.98% | -- | -- | -- | |
| Capital Expenditure | -1,136.73% | -- | -- | -- | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | 161.37% | -- | -- | -- | |
| Cash from Investing | 160.84% | -- | -- | -- | |
| Total Debt Issued | -- | -- | -- | -- | |
| Total Debt Repaid | -- | -- | -- | -- | |
| Issuance of Common Stock | 33,428.01% | -- | -- | -- | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -89.17% | -- | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | -- | -- | -- | -- | |
| Cash from Financing | 85.86% | -- | -- | -- | |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | 1,015.53% | -- | -- | -- | |